-Janssen Pharmaceutical - U.S. FDA Approves TALVEY, a First-in-Class Bispecific Therapy for the Treatment of Patients with Heavily Pretreated Multiple Myeloma

Press/Media

Period11 Aug 2023

Media coverage

2

Media coverage